6-(4-hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

US8686150B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Stephanie Hachtel · Frankfurt am Main, DE
• Oliver Plettenburg · Kelkheim, DE
• Christian Schoenau · Hochheim, DE
• Matthias Loehn · Frankfurt am Main, DE
• Stefania PFEIFFER-MAREK · Frankfurt, DE
• Maria MENDEZ-PEREZ · Frankfurt am Main, DE
• Aimo Kannt · Dreieich, DE
• Juergen Dedio · Frankfurt, DE
• Markus Kohlmann · Frankfurt am Main, DE
• Alexander Schiffer · Frankfurt am Main, DE
• Guillaume BEGIS · Paris, FR
• Olivier Duclos · Paris, FR
• Frederic Jeannot · Paris, FR

Key dates

• Filing date: Sep 27, 2012
• Grant date: Apr 1, 2014
• Expiry date: Sep 27, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I,in which R1, R2, R3, R4, R5, R6 and R7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.